MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Dexcom inks 5-year diabetes research pact with U of Virginia

Dexcom inks 5-year diabetes research pact with U of Virginia

By

Dexcom updated logoDexcom (NSDQ:DXCM) announced today that it signed a five-year collaboration agreement with the University of Virginia for CGM research.

The partnership will focus on advancing Dexcom’s automated insulin delivery technology and exploring the use of continuous glucose monitoring (CGM) tools outside the Type 1 diabetes market, which includes inpatient hospital use, Type 2 diabetes and gestational diabetes, according to a news release.

San Diego-based Dexcom acquired its automated insulin delivery technology from Virginia-based startup TypeZero Technologies in 2018 and established a Charlottesville, Va., office, offering opportunities to collaborate with the University of Virginia, which is located in Charlottesville.

Dexcom’s next-generation closed-loop algorithms will be refined and piloted in a series of clinical trials as part of the collaboration, while the company’s Charlottesville team will expand in conjunction with the research collaboration, which will be spearheaded by the university’s Center for Diabetes Technology and will engage the School of Engineering, the School of Data Science and the School of Medicine at the university.

“Dexcom is committed to bringing innovative continuous glucose monitoring-based solutions to empower customers and clinicians toward greater health outcomes,” Dexcom chairman, president & CEO Kevin Sayer said in the release. “We are investing heavily in research and development efforts that explore new diagnostic tools and treatments. By partnering with a top-tier research institution like the University of Virginia, we hope to bring better CGM solutions to patients much faster than we could alone.”

Dexcom and the University of Virginia intend to commence their partnership in late 2020, with the company providing research funding to the university over a five-year period.

“The University of Virginia has become one of the world’s leading research institutes for diabetes technology,” University of Virginia president Jim Ryan said. “This expanded commitment from Dexcom ensures that research conducted on Grounds has a clear path to enrich and improve the lives of patients and caregivers managing this complicated and all too common disease.”

In case you missed it

RSS From Medical Design & Outsourcing

  • One of FDA’s top lawyers leaves to join Greenberg Traurig
    Greenberg Traurig recently announced that James C. Fraser, a former associate chief counsel for litigation at the FDA, has joined its Litigation and Health Care & FDA practices in Washington, D.C. Fraser left FDA in August. He has more than 16 years of experience in life sciences litigation and most recently worked in conjunction with… […]
  • September 2021 Issue: Our latest Medical Device Handbook is out!
      Making medical devices: Everything you need to know The innovation-fueled evolution of drug eluting stents Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’ Getting the inside scoop behind top medtech innovations Autumn is upon us, and it is once again time to sip a pumpkin spice latte  — or a pumpkin beer —… […]
  • Steris launches two new vaporized hydrogen peroxide biodecontamination systems
    Steris has launched the next generation of its vaporized hydrogen peroxide (VHP) biodecontamination systems to achieve 6-log bioburden reduction in good-manufacturing-practice pharmaceutical, medical device and research environments. It’s possible to integrate the new VHP 100i and 1000i systems into a facility’s building automation and HVAC systems, running a decontamination cycle at programmed intervals or at… […]
  • First witnesses in Elizabeth Holmes federal fraud trial take the stand
    Two of the prosecution’s witnesses took the stand yesterday on the second day of Elizabeth Holmes’ federal fraud trial. Theranos’ former financial controller San Ho Spivey, who is referred to as Danise Yam, took the stand and testified about the company’s financial condition during its heyday. Yam told Assistant U.S. Attorney Robert Leach that Theranos… […]
  • Axonics loses IP challenge to Medtronic patents
    Medtronic (NYSE:MDT) announced that it picked up three victories in an intellectual property (IP) dispute against Axonics (NSDQ:AXNX) over sacral neuromodulation devices. According to a news release, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected Axonics’ attempt to invalidate three Medtronic patents in its IP infringement lawsuit related to Medtronic’s InterStim neuromodulation device… […]
  • Cepheid wins EUA for new version of COVID-19, flu, RSV combination diagnostic
    Cepheid announced today that it received FDA emergency use authorization (EUA) for its Xpert Xpress CoV-2/Flu/RSV Plus diagnostic. Sunnyvale, California-based Cepheid designed its Xpert Xpress Plus as a rapid molecular diagnostic test for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B and respiratory syncytial virus (RSV). Get the full story at our… […]
  • Stratasys expands anatomical modeling services for healthcare
    Stratasys Direct Manufacturing now offers anatomical modeling and consultative services for the healthcare industry. The Stratasys (NASDAQ: SSYS) subsidiary opened its new Healthcare Print Center in Eden Prairie, Minnesota, and soft-launched the new offerings with an invite-only beta test for medical device manufacturers. Over the past 13 weeks, Stratasys J750 Digital Anatomy printers have created… […]
  • FDA clears NeuroOne’s Evo sEEG electrode
    NeuroOne Medical Technologies (NMTC) announced that it received FDA 510(k) clearance for its Evo sEEG electrode technology. Eden Prairie, Minnesota-based NeuroOne’s Evo sEEG electrode technology received clearance for temporary (less than 24 hours) use with recording, monitoring and stimulation equipment for the recording, monitoring and stimulation of electrical signals at the subsurface level of the brain,… […]
  • Cardinal Health docks executive bonuses over opioid costs
    Cardinal Health’s board of directors reduced bonus payouts for CEO Mike Kaufmann and his four top-paid executives due to the cost of opioid litigation. After pressure from investors, Cardinal Health (NYSE:CAH) for the first time has disclosed how its board of directors factored the opioid litigation settlement costs into the pay packages of Kaufmann, Chief… […]
  • Creating Safe Usable Medical Device Solutions: Free webinar from MedAcuity and Fathom Consulting
    MedAcuity — a Boston-based software development partner for medical device makers — and Minneapolis-based Fathom Consulting are offering a free webinar exploring “the importance of design and development collaboration to keep projects on time and on budget.” The four panelists — Mary Donnelly and Elizabeth Sipple from Fathom and Bruce Johnston and Mike Kropp from… […]
  • Steris launches new cleanroom disinfectant wipes
    Steris Life Sciences has launched a new disinfectant wipe for cleanroom surfaces. The new Vesta-Syde SQ 64 sterile wipes are packaged with a separate, internal pouch that contains the active ingredient, quaternary ammonium.  The internal pouch design “allows for maximum chemical stability while offering a simple, convenient, and consistent method to saturate the wipes,” Steris… […]